The US Food and Drug Administration (FDA) has granted 510(k) clearance to SleepRes’ Kairos positive airway pressure (KPAP)-powered Kricket PAP device for the treatment of obstructive sleep apnoea (OSA).
Intended for patients weighing more than 66lb, the device is suitable for use in hospitals, institutional settings, homes, and sleep centres.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The KPAP sleep therapy platform is developed to offer an adaptive and patient-focused alternative to traditional continuous positive airway pressure (CPAP) therapy.
According to the company, the KPAP technology is designed to adjust pressure delivery throughout the breathing cycle, in contrast to the fixed pressure maintained by conventional CPAP devices.
This approach aims to synchronise therapy with the patients’ natural breathing patterns and airway dynamics, potentially reducing discomfort and improving sleep tolerance.
SleepRes founder and KPAP inventor William Noah said: “Today completes a 4+ year pursuit to provide my own patients with technology designed to emulate natural breathing and address the discomfort and pressure intolerance common with traditional CPAP.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe device offers KPAP, traditional CPAP, and automatic PAP therapy modes.
SleepRes is planning to introduce the Kricket device commercially in the first half of 2026 and is currently preparing to expand manufacturing, develop clinical collaborations, and offer insights on the KPAP system before the launch.
SleepRes’ chief medical officer David White said: “Kricket opens the door to a new category of positive airway pressure therapy that prioritises comfort, the patient’s ability to adapt, and real-world use, while still delivering the therapy patients need.
“That balance is critical if we want to meaningfully improve long-term outcomes for people living with obstructive sleep apnoea.”
